Susquehanna International Group, LLP Geron Corp Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

A detailed history of Susquehanna International Group, LLP transactions in Geron Corp stock. As of the latest transaction made, Susquehanna International Group, LLP holds 228,426 shares of GERN stock, worth $911,419. This represents 0.0% of its overall portfolio holdings.

Number of Shares

228,426

Previous 185,406 23.2%

Holding current value

$911,419

Previous $786,000 31.93%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$4.17 - $4.99 $179,393 - $214,669	43,020 Added 23.2%	228,426 $1.04 Million
Q2 2024 Aug 15, 2024	SELL	$3.1 - $5.09 $918,548 - $1.51 Million	-296,306 Reduced 61.51%	185,406 $786,000
Q1 2024 May 07, 2024	SELL	$1.75 - $3.44 $381,029 - $748,994	-217,731 Reduced 31.13%	481,712 $1.59 Million
Q4 2023 Feb 14, 2024	BUY	$1.74 - $2.31 $396,083 - $525,834	227,634 Added 48.25%	699,443 $1.48 Million
Q3 2023 Nov 14, 2023	SELL	$2.11 - $3.28 $568,668 - $883,996	-269,511 Reduced 36.36%	471,809 $1 Million
Q2 2023 Aug 11, 2023	SELL	$1.97 - $3.69 $984,988 - $1.84 Million	-499,994 Reduced 40.28%	741,320 $2.38 Million
Q1 2023 May 16, 2023	BUY	$2.14 - $3.4 $2.22 Million - $3.52 Million	1,036,400 Added 505.77%	1,241,314 $2.69 Million
Q4 2022 Feb 14, 2023	SELL	$2.03 - $2.42 $429,314 - $511,793	-211,485 Reduced 50.79%	204,914 $495,000
Q3 2022 Nov 14, 2022	BUY	$1.67 - $2.94 $513,688 - $904,338	307,598 Added 282.72%	416,399 $975,000
Q2 2022 Aug 15, 2022	SELL	$1.19 - $1.65 $70,165 - $97,288	-58,963 Reduced 35.15%	108,801 $169,000
Q1 2022 May 16, 2022	SELL	$0.99 - $1.6 $69,783 - $112,780	-70,488 Reduced 29.59%	167,764 $228,000
Q4 2021 Feb 14, 2022	BUY	$1.22 - $1.72 $10,029 - $14,140	8,221 Added 3.57%	238,252 $291,000
Q3 2021 Nov 15, 2021	BUY	$1.2 - $1.5 $1,124 - $1,405	937 Added 0.41%	230,031 $315,000
Q2 2021 Aug 11, 2021	BUY	$1.25 - $1.83 $131,892 - $193,090	105,514 Added 85.38%	229,094 $323,000
Q1 2021 May 17, 2021	SELL	$1.52 - $2.1 $339,212 - $468,648	-223,166 Reduced 64.36%	123,580 $195,000
Q4 2020 Feb 16, 2021	SELL	$1.55 - $2.05 $34,031 - $45,009	-21,956 Reduced 5.95%	346,746 $551,000
Q3 2020 Nov 16, 2020	BUY	$1.59 - $2.19 $224,027 - $308,566	140,898 Added 61.85%	368,702 $641,000
Q2 2020 Aug 14, 2020	SELL	$1.05 - $2.18 $265,847 - $551,949	-253,188 Reduced 52.64%	227,804 $497,000
Q1 2020 May 15, 2020	SELL	$0.89 - $1.49 $31,223 - $52,273	-35,083 Reduced 6.8%	480,992 $573,000
Q4 2019 Feb 14, 2020	SELL	$1.27 - $1.54 $122,068 - $148,020	-96,117 Reduced 15.7%	516,075 $702,000
Q3 2019 Nov 14, 2019	BUY	$1.15 - $1.59 $174,106 - $240,721	151,397 Added 32.86%	612,192 $814,000
Q2 2019 Aug 16, 2019	BUY	$1.37 - $2.02 $21,673 - $31,956	15,820 Added 3.56%	460,795 $650,000
Q2 2019 Aug 14, 2019	BUY	$1.37 - $2.02 $384,112 - $566,355	280,374 Added 170.34%	444,975 $627,000
Q1 2019 May 15, 2019	SELL	$1.01 - $1.83 $228,928 - $414,791	-226,662 Reduced 57.93%	164,601 $273,000
Q4 2018 Feb 14, 2019	SELL	$0.98 - $1.85 $749,318 - $1.41 Million	-764,611 Reduced 66.15%	391,263 $391,000
Q3 2018 Nov 14, 2018	BUY	$1.76 - $6.38 $1.83 Million - $6.63 Million	1,039,075 Added 889.63%	1,155,874 $2.03 Million
Q2 2018 Aug 14, 2018	SELL	$3.29 - $4.82 $141,552 - $207,380	-43,025 Reduced 26.92%	116,799 $401,000
Q1 2018 May 15, 2018	SELL	$1.81 - $5.98 $726,447 - $2.4 Million	-401,352 Reduced 71.52%	159,824 $679,000
Q4 2017 Feb 14, 2018	BUY	$1.8 - $2.32 $894,394 - $1.15 Million	496,886 Added 772.88%	561,176 $1.01 Million
Q3 2017 Nov 14, 2017	BUY	$1.99 - $2.65 $127,937 - $170,368	64,290	64,290 $140,000

Others Institutions Holding GERN

# of Institutions

275

Shares Held

491M

Call Options Held

1.87M

Put Options Held

690K

View Full List

About GERON CORP

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.51B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

More about GERN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Geron Corp Transaction History